
# Medical and Prescription Drug Dashboard - All Members

Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

# 1. Quality Metrics\*



\*Quality Metrics are based on Incurred Rolling Year.


#### 3. Well Care and Preventive Visits

#### Previous Current Trend Benchmark Visits Per 1000 Well Baby 5756.0 825.5 1.2% 5,374.2 Visits Per 1000 Well Child 832.9 02.5 8.4% 757.8 Visits Per 1000 Prevent Adult 389.8 27.2 9.6% 360.0


#### 4. Medical Plan Eligibility

	Previous	Current	Trend
Average Employees	69,904	71,020	2%
Average Members	124,109	125,442	1%
Family Size	1.8	1.8	-1%
Member Age	42.8	42.9	0%
Members % Male	45%	45%	0% pts

# 6. Cost Sharing



## 2. High Cost Claimants\*



\*Members with >=\$100,000 in Medical and Rx Net Payments

	Previous	Current	Trend
Patients	942	1,027	9%
Patients per 1,000	7	7.5	8%
Payments (in millions)	\$178.4	\$201.7	13%
Payment per Patient	\$189,374	\$196,361	4%

#### 5. Price and Use



IP Price	IP Use	LUS	OP Price	OP Use	ER USE	KX Pric	e (AII)	RX USE (AII)
Inpatient				Current	Benchi	nark		Trend
Allowed per A	dmit			\$22,423	\$27	7,604	•	5%
Admits per 1,	000			84.2		55.3		-6%
Days LOS				5.1		4.5		5%
Outpatient								
Allowed per S	ervice			\$125		\$124	•	3%
Services PMPY	′			41.6		30.6		4%
Emergency Ro	om Visits	per 1,000		348		226		0%
Prescription	Drugs							
Allowed/Days	Supply			\$2				3%
Days Supply F	PMPY			636				0%
Specialty Dr	ugs							
Allowed/Days	Supply			\$93				3%
Days Supply F	PMPY			9				15%
All Prescript	ion Drugs	1						
Allowed/Days	Supply			\$4		\$4	•	8%
Days Supply F	PMPY			645		373	•	0%
<ul> <li>Represents a lo</li> </ul>	wer than -3	% comparisor	to the ber	nchmark				

◆ Represents a comparison to the benchmark within +/-3%

Represents a higher than 3% comparison to the benchmark


IBM **Watson Health** 

Apr 24, 2019 1 of 9

# **Medical and Prescription Drug Dashboard - All Members**


Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

# 7. Top Medical Conditions (by cost)




	Condition	Allowed Amount Med	Patients Med	Med Allowed /Patient
1	Prevent/Admin HIth Encounters	\$35,727,045	82,943	\$431
2	Osteoarthritis	\$31,306,249	13,513	\$2,317
3	Spinal/Back Disord, Low Back	\$26,039,836	16,283	\$1,599
4	Arthropathies/Joint Disord NEC	\$24,953,694	30,634	\$815
5	Coronary Artery Disease	\$24,371,460	5,914	\$4,121
6	Chemotherapy Encounters	\$23,817,795	587	\$40,575
7	Respiratory Disord, NEC	\$22,094,717	15,780	\$1,400
8	Gastroint Disord, NEC	\$21,034,863	16,444	\$1,279
9	Pregnancy without Delivery	\$20,325,709	2,564	\$7,927
10	Renal Function Failure	\$19,284,466	3,540	\$5,448


#### 8. Screening Rates




#### 9. Chronic Condition Prevalence



## 10. Prescription Drug Metrics




	Therapeutic Class	Allowed Amount Rx	Patients Rx	Rx Allowed /Patient
1	Immunosuppressants, NEC	\$32,766,911	1,112	\$29,467
2	Antidiabetic Agents, Misc	\$22,407,960	9,930	\$2,257
3	Antidiabetic Agents, Insulins	\$18,266,048	3,527	\$5,179
4	Molecular Targeted Therapy	\$15,992,723	185	\$86,447
5	Biological Response Modifiers	\$14,973,416	186	\$80,502
6	Coag/Anticoag, Anticoagulants	\$11,122,823	4,332	\$2,568
7	Adrenals & Comb, NEC	\$9,565,328	25,053	\$382
8	Stimulant, Amphetamine Type	\$9,475,479	5,505	\$1,721
9	Antivirals, NEC	\$8,037,380	8,246	\$975
10	Antihyperlipidemic Drugs, NEC	\$7,937,348	29,185	\$272



# State of Delaware Medical and Prescription Drug Dashboard - Active Employees

Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

## 1. Quality Metrics\*



\*Quality Metrics are based on Incurred Rolling Year.


#### 3. Well Care and Preventive Visits

# Visits Per 1000 Well Baby 5757.6 5831.9 1.3% 5374.2 • Visits Per 1000 Well Child 832.5 901.6 8.3% 757.8 • Visits Per 1000 Prevent Adult 455.8 497.3 9.1% 325.0 •

#### 4. Medical Plan Eligibility


	Previous	Current	Trend
Average Employees	37,783	38,112	1%
Average Members	88,525	88,884	0%
Family Size	2.3	2.3	0%
Member Age	33.0	32.9	0%
Members % Male	47%	46%	0% pts

## 6. Cost Sharing



Out-of-Pocket as a % of Allowed Amount


## 2. High Cost Claimants\*



\*Members with >=\$100,000 in Medical and Rx Net Payments

	Previous	Current	Trend
Patients	672	743	11%
Patients per 1,000	6.8	7.5	10%
Payments (in millions)	\$125.4	\$138.8	11%
Payment per Patient	\$186,620	\$186,750	0%

#### 5. Price and Use



3 of 9

ibM Watson Health

# State of Delaware Medical and Prescription Drug Dashboard - Active Employees


Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

# 7. Top Medical Conditions (by cost)




	Condition	Allowed Amount Med	Patients Med	Med Allowed /Patient
1	Prevent/Admin HIth Encounters	\$27,340,884	62,112	\$440
2	Pregnancy without Delivery	\$19,758,945	2,500	\$7,904
3	Chemotherapy Encounters	\$13,850,214	206	\$67,234
4	Newborns, w/wo Complication	\$13,848,267	1,178	\$11,756
5	Osteoarthritis	\$13,310,732	5,117	\$2,601
6	Arthropathies/Joint Disord NEC	\$13,211,466	17,439	\$758
7	Spinal/Back Disord, Low Back	\$12,921,057	8,900	\$1,452
8	Coronary Artery Disease	\$12,284,462	1,355	\$9,066
9	Gastroint Disord, NEC	\$11,965,861	9,864	\$1,213
10	Respiratory Disord, NEC	\$11,453,142	7,301	\$1,569


#### 8. Screening Rates




#### 9. Chronic Condition Prevalence



## 10. Prescription Drug Metrics



	Allowed Alliount RX A Patients RX				
	Therapeutic Class	Allowed Amount Rx	Patients Rx	Rx Allowed /Patient	
1	Immunosuppressants, NEC	\$19,645,158	629	\$31,232	
2	Antidiabetic Agents, Misc	\$8,466,737	4,439	\$1,907	
3	Stimulant, Amphetamine Type	\$8,332,212	4,849	\$1,718	
4	Antidiabetic Agents, Insulins	\$7,053,611	1,437	\$4,909	
5	Biological Response Modifiers	\$5,759,618	80	\$71,995	
6	Antivirals, NEC	\$5,405,914	5,975	\$905	
7	Molecular Targeted Therapy	\$4,728,521	54	\$87,565	
8	Adrenals & Comb, NEC	\$4,138,431	16,196	\$256	
9	Misc Therapeutic Agents, NEC	\$3,524,473	2,521	\$1,398	
10	Psychother, Antidepressants	\$2,942,442	13,127	\$224	




Apr 24, 2019 4 of 9

# **Medical and Prescription Drug Dashboard - Early Retirees**

Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

# 1. Quality Metrics\*



\*Quality Metrics are based on Incurred Rolling Year.


#### 3. Well Care and Preventive Visits

# Previous Current Trend Benchmark Visits Per 1000 Well Baby 5268.4 5581.4 5.9% 5374.2 ■ Visits Per 1000 Well Child 844.7 994.5 17.5% 757.8 ● Visits Per 1000 Prevent Adult 463.4 503.9 8.7% 459.0 ●

## 4. Medical Plan Eligibility


	Previous	Current	Trend
Average Employees	5,936	5,926	0%
Average Members	9,151	9,268	1%
Family Size	1.5	1.6	1%
Member Age	50.9	50.5	-1%
Members % Male	41%	42%	1% pts

# 6. Cost Sharing



Out-of-Pocket as a % of Allowed Amount


## 2. High Cost Claimants\*



\*Members with >=\$100,000 in Medical and Rx Net Payments

	Previous	Current	Trend
Patients	226	237	5%
Patients per 1,000	20	19.9	0%
Payments (in millions)	\$35.7	\$39.2	10%
Payment per Patient	\$157,959	\$165,456	5%

#### 5. Price and Use



Apr 24, 2019 5 of 9



# **Medical and Prescription Drug Dashboard - Early Retirees**


Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

## 7. Top Medical Conditions (by cost)




	Condition	Allowed Amount Med	Patients Med	Med Allowed /Patient
1	Osteoarthritis	\$4,309,966	1,411	\$3,055
2	Chemotherapy Encounters	\$3,726,377	80	\$46,580
3	Gastroint Disord, NEC	\$3,547,830	1,315	\$2,698
4	Prevent/Admin HIth Encounters	\$3,399,403	6,679	\$509
5	Coronary Artery Disease	\$2,752,276	434	\$6,342
6	Spinal/Back Disord, Low Back	\$2,720,763	1,514	\$1,797
7	Respiratory Disord, NEC	\$2,555,496	1,273	\$2,007
8	Arthropathies/Joint Disord NEC	\$2,281,132	2,774	\$822
9	Diabetes	\$2,162,364	1,879	\$1,151
10	Condition Rel to Tx - Med/Surg	\$2,089,715	304	\$6,874


#### 8. Screening Rates




#### 9. Chronic Condition Prevalence



## 10. Prescription Drug Metrics



	Allowed Allount RX Fatients RX					
	Therapeutic Class	Allowed Amount Rx	Patients Rx	Rx Allowed /Patient		
1	Immunosuppressants, NEC	\$3,203,052	124	\$25,831		
2	Antidiabetic Agents, Misc	\$2,323,167	1,140	\$2,038		
3	Biological Response Modifiers	\$1,997,433	29	\$68,877		
4	Molecular Targeted Therapy	\$1,854,787	27	\$68,696		
5	Antidiabetic Agents, Insulins	\$1,854,484	385	\$4,817		
6	Antivirals, NEC	\$817,321	655	\$1,248		
7	Antidiabetic Ag, SGLT Inhibitr	\$779,184	223	\$3,494		
8	Adrenals & Comb, NEC	\$763,947	2,034	\$376		
9	Antihyperlipidemic Drugs, NEC	\$708,990	3,240	\$219		
10	Stimulant, Amphetamine Type	\$645,716	408	\$1,583		




Apr 24, 2019 6 of 9

# **Medical and Prescription Drug Dashboard - Medicare Retirees**

Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

# 1. Quality Metrics\*



\*Quality Metrics are based on Incurred Rolling Year.


#### 3. Well Care and Preventive Visits

	Previous	Current	Trend	Benchmark	
Visits Per 1000 Prevent Adult	204.7	236.0	15.3%	440.0	


# 4. Medical Plan Eligibility

	Previous	Current	Trend
Average Employees	23,823	24,576	3%
Average Members	23,904	24,712	3%
Family Size	1.0	1.0	0%
Member Age	73.2	73.1	0%
Members % Male	42%	42%	0% pts

# 6. Cost Sharing



## 2. High Cost Claimants\*



\*Members with >=\$100,000 in Medical and Rx Net Payments

	Previous	Current	Trend
Patients	126	154	22%
Patients per 1,000	5	5.9	17%
Payments (in millions)	\$14.5	\$21.1	45%
Payment per Patient	\$115,284	\$137,001	19%

#### 5. Price and Use



IP Price	IP Use	LOS	OP Price	OP Use	ER Use	Rx Pric	e (All)	Rx Use (All)
Inpatient				Current	Bench	mark		Trend
Allowed per A	dmit			\$16,852	\$3	1,055	•	7%
Admits per 1,	000			169.7		56.4		-5%
Days LOS				5.7		4.8		3%
Outpatient								
Allowed per S	Service			\$110		\$123	•	4%
Services PMP	Υ			73.3		31.0		2%
Emergency Re	oom Visits	per 1,000		547		225		0%
Prescription	Drugs							
Allowed/Days	Supply			\$2				3%
Days Supply I	PMPY			1,448				-2%
Specialty Dr	ugs							
Allowed/Days	Supply			\$101				8%
Days Supply I	PMPY			17				12%
All Prescript	ion Drugs							
Allowed/Days	Supply			\$3		\$4	•	9%
Days Supply I	PMPY			1,465		387	•	-2%
<ul> <li>Represents a le</li> </ul>	ower than -3°	% comparisor	to the ber	nchmark				

◆ Represents a comparison to the benchmark within +/-3%

Represents a higher than 3% comparison to the benchmark

Apr 24, 2019 7 of 9

# **Medical and Prescription Drug Dashboard - Medicare Retirees**


Previous Period: Apr 2017 - Mar 2018 (Paid) Current Period: Apr 2018 - Mar 2019 (Paid)

# 7. Top Medical Conditions (by cost)




	Condition	Allowed Amount Med	Patients Med	Med Allowed /Patient
1	Osteoarthritis	\$12,879,373	6,539	\$1,970
2	Spinal/Back Disord, Low Back	\$9,616,772	5,560	\$1,730
3	Renal Function Failure	\$8,980,288	2,302	\$3,901
4	Eye Disorders, Degenerative	\$8,971,061	7,997	\$1,122
5	Coronary Artery Disease	\$8,615,059	3,813	\$2,259
6	Arthropathies/Joint Disord NEC	\$8,431,796	9,724	\$867
7	Respiratory Disord, NEC	\$7,282,390	6,559	\$1,110
8	Cerebrovascular Disease	\$6,504,843	2,900	\$2,243
9	Hypertension, Essential	\$6,194,104	12,268	\$505
10	Chemotherapy Encounters	\$5,720,450	296	\$19,326


#### 8. Screening Rates




#### 9. Chronic Condition Prevalence



## 10. Prescription Drug Metrics



	7 moved 7 mount for = 1 defends for					
	Therapeutic Class	Allowed Amount Rx	Patients Rx	Rx Allowed /Patient		
1	Antidiabetic Agents, Misc	\$10,782,288	4,246	\$2,539		
2	Immunosuppressants, NEC	\$9,319,605	356	\$26,179		
3	Molecular Targeted Therapy	\$8,921,428	110	\$81,104		
4	Antidiabetic Agents, Insulins	\$8,509,417	1,636	\$5,201		
5	Coag/Anticoag, Anticoagulants	\$7,828,520	2,920	\$2,681		
6	Biological Response Modifiers	\$6,683,154	79	\$84,597		
7	Antihyperlipidemic Drugs, NEC	\$4,597,000	14,925	\$308		
8	Adrenals & Comb, NEC	\$4,220,105	6,385	\$661		
9	Misc Therapeutic Agents, NEC	\$3,297,911	3,190	\$1,034		
10	Gastrointestinal Drug Misc,NEC	\$3,216,500	6,460	\$498		



Apr 24, 2019 8 of 9

# **Medical and Prescription Drug Dashboard**

# **Dashboard Glossary**

#### Genera

- Claims are completed for claims incurred but not yet recorded (IBNR)
- Benchmark represents 2017 US Total MarketScan norms that are age, gender, geographic, and/or severity adjusted as appropriate
- PMPY stands for Per Member Per Year and is weighted based on the number of months a member was enrolled in medical benefits
- Allowed Amount (Allowed) is the amount of submitted charges eligible for payment for medical and prescription drug claims; it is the amount eligible after applying pricing guidelines, but before deducting third party, copayment, coinsurance or deductible amounts.
- Net Payment (Payment) is the net amount paid by the company for medical and prescription drug claims; it represents the amount after all pricing guidelines have been applied, and all third party, copayment, coinsurance, and deductible amounts have been subtracted
- Inpatient (IP) represents claims for services provided under medical coverage in an acute inpatient setting; acute inpatient settings include inpatient hospitals, birthing centers, inpatient psychiatric facilities, and residential substance abuse treatment facilities
- Outpatient (OP) represents claims for medical services provided in any non-inpatient setting
- Prescription Drug (Rx) represents any claim paid under the pharmacy benefit
- Patients represents any member with a claim for the service (e.g., medical or prescription drug) being reported during the time period

#### 1. Well Care and Preventive Visits

#### 2. High Cost Claimants

- High Cost Claimants (HCCs) are members with \$100,000 or more in medical and prescription drug net payments incurred during the year
- Non-High Cost Claimants (HCCs) are members with less than \$100,000 in medical and prescription drug net payments incurred during the year

#### 3. Quality Metrics

#### 4. Medical Plan Eligibility

- Average Employees represents the number of employees with medical coverage; each employee is counted once for each month of their eligibility, then the total is averaged across the total number of months of eligibility during the time period
- Average Members represents the number of members with medical coverage; each member is counted once for each month of their eligibility, then the total is averaged across the total number of months of eligibility during the time period
- \* Family Size represents the average number of covered members per subscriber
- Member Age represents the average age of covered members during the year
- Members % Male represents the number of male members as a percent of total members

#### 5. Risk Score

#### The Member Risk Score represents the DCG non-rescaled concurrent score

- The Member Risk Score is produced using the Verisk DCG® model
- This model measures the health risk of a population relative to the national average as of the time the model was developed (i.e., 100)

#### 6. Price and Use

- Current represents your Price or Use rate in the Current year
- Benchmark represents the U.S. Total MarketScan norm for the Price or Use rate
- \* The Symbol next to the Benchmark represents your Current rate compared to the Norm
- The **Trend** represents your year-over-year trend for the Price or Use rate

#### 7. Cost Sharing

#### The cost sharing percentage represents Out-of-Pocket divided by Allowed Amounts

Out-of-Pocket represents the amount paid out-of-pocket by the member for facility, professional, and prescription drug services; this generally includes coinsurance, copayment, and deductible amounts

#### 8. Top Medical Conditions (by cost)

- Conditions represent Truven Health Clinical Condition groupings, based on ICD-9 and ICD-10 diagnosis codes
- Clinical conditions include medical claims (i.e., prescription drug is not included)
- Note: The clinical condition of Signs/Symptoms/Oth Cond, NEC is excluded from this exhibit

#### 9. Screening Rates

- Cholesterol identifies lipid screening tests for males aged 35+ years and females aged 45+ years; lipid screening tests include lipid panels, serum cholesterol tests, blood lipoprotein tests (e.g., HDL, LDL), and triglyceride tests [source for age and gender criteria: US Preventive Services Task Force]
- " Cervical Cancer identifies the percentage of females aged 21 to 64 who received cervical cancer screening services [source for age, gender, procedure, diagnosis, and revenue code criteria: NCQA HEDIS 2014]
- Breast Cancer identifies the percentage of females aged 50 to 74 who received mammography services [source for age, gender, diagnosis, procedure, and revenue code criteria: NCQA HEDIS 2014]
- Colon Cancer identifies the percentage of adults aged 50 to 75 who received colon cancer screening services [source for age, diagnosis and procedure criteria: NCQA HEDIS 2014]

#### 10. Chronic Condition Prevalence

- Conditions represent Truven Health Clinical Condition groupings, based on ICD-9 and ICD-10 diagnosis codes
- Chronic conditions identified based on medical claims

#### 11. Prescription Drug Metrics

- Therapeutic Class represents the Redbook Therapeutic Class Intermediary
- Scripts % Generic is the number of prescriptions filled with a generic drug, expressed as a percentage of all prescriptions filled
- Generic Efficiency Rate is the number of prescriptions filled with a generic drug, expressed as a percentage of all prescriptions filled that could have been filled with a generic drug
- Days Supply % Mail Order is the percent of all prescription days supply filled via mail order
- \*\* Allowed Amount % Specialty is the percent of total prescription drug allowed amounts that were for medications considered to be specialty drugs (identified using Truven Health Service Categories)

